The Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma field

CALYM ASH 2017 presentations

12 oral presentations

- Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years. **G Salles**

- Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy. **E Bachy**

- Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial. **O Casasnovas**

- PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. **L Fornecker**

- Rituximab Maintenance After First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized European MCL Elderly Trial. **E Hoster**

- A New Immunohistochemical Algorithm Using Four Antibodies Has a High Concordance with Gene Expression Profiling Defined ABC and GCB Â Diffuse Large B-Cell Lymphoma. **T Molina**

- Lenalidomide treatment restores in vivo T cell activity in relapsed/refractory FL and DLBCL. **C Menard**

- Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers . **C Rossi**

- Germinal Center Program De-Synchronization and Intra-Patient Heterogeneity in Follicular Lymphoma B-Cells Revealed By Integrative Single-Cell Analysis. **P Milpied**
Combined Genotype Analysis of Tumor and Cell-Free DNA By Ultra-Deep Targeted Sequencing: Correlation with PET-Scan Imaging in a Prospective Cohort of Diffuse Large B-Cell Lymphoma Patients. F Jardin

7 Posters

• Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study. C. Thieblemont

• Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials. M Maurer

• R-DHA-Oxaliplatin before autologous stem cell transplantation prolongs PFS and OS as compared to R-DHA-Carboplatin and R-DHA-cisplatin in patients with mantle cell lymphoma, a subgroup analysis of the LyMa trial. S Le Gouill

• P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the LYMA Trial in the LYSA Group. D Canioni

• Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group. D Canioni

• Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center. G Aussedat

• Follicular Lymphoma Regulatory T Cell Function and Origin. K Tarte

Education session "The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma"

• Role of the Microenvironment Across Histological Subtypes of NHL. K. Tarte